Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh. Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical ...

This leaflet answers some common questions about Atrovent Inhalation Solution. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

This leaflet answers some common questions about Atrovent UDV. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

Drug-resistant infections occur when pathogens change in ways that render antimicrobial drugs ineffective. As a result, the pathogens survive and continue to spread. When infections are treatable with ...

The drug companies say they’ve made the changes because they’re committed to helping ... Boehringer Ingelheim is also planning to cut the list prices for Spiriva HandiHaler and Atrovent HFA. Other ...

One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, ...

Albuterol sulfate 90mcg/inh; metered-dose aerosol (with a dose counter); CFC-free. Proair HFA (albuterol sulfate) Inhalation Aerosol is supplied as a pressurized aluminum canister with a red ...

Any Australian who has filled a prescription at the chemist will have been asked if they want a branded product or the generic version. And with consumers looking to cut costs wherever they can ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

But a generic version (and the active ingredient) of this popular medication, sildenafil, is widely available from several drug manufacturers at a fraction of the cost. Read on to find out more ...

The average drug now costs more than US$1 billion to develop and takes more than a decade to reach the market 1. And for every success, there are nine drug candidates that fail clinical trials 2.